Compare OSS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | MGNX |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.6M | 220.6M |
| IPO Year | 2017 | 2013 |
| Metric | OSS | MGNX |
|---|---|---|
| Price | $15.42 | $3.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $10.00 | $5.00 |
| AVG Volume (30 Days) | ★ 2.1M | 585.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $37,027,382.00 | ★ $149,500,000.00 |
| Revenue This Year | $22.19 | N/A |
| Revenue Next Year | $20.67 | $3.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $2.37 | $1.19 |
| 52 Week High | $16.95 | $3.88 |
| Indicator | OSS | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 75.79 | 61.89 |
| Support Level | $7.45 | $1.48 |
| Resistance Level | N/A | $3.88 |
| Average True Range (ATR) | 1.46 | 0.22 |
| MACD | 0.67 | -0.01 |
| Stochastic Oscillator | 82.15 | 66.68 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.